Russell Investments Group
AVBP icon

Russell Investments Group’s ArriVent BioPharma AVBP Stock Holding History

Russell Investments Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
9,158
+7,090
+343% +$209K ﹤0.01% 2994
2026
Q1 		$47.7K Hold
2,068
– – ﹤0.01% 3344
2025
Q4 		$41.6K Hold
2,068
– – ﹤0.01% 3367
2025
Q3 		$38.2K Buy
2,068
+2,047
+9,748% +$40.2K ﹤0.01% 3377
2025
Q2 		$457 Buy
+21
New +$436 ﹤0.01% 3755

Other funds holding AVBP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Russell Investments Group's AVBP Position: Q2 2026 in Review

Russell Investments Group increased its ArriVent BioPharma (AVBP) stake by 343% in Q2 2026, buying an estimated $209K and bringing the position to 9,158 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Russell Investments Group first reported a position in AVBP in Q2 2025 and has held it in 5 quarters since. 47 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Russell Investments Group held 9,158 shares of ArriVent BioPharma worth $318K as of Q2 2026.
  • Russell Investments Group bought 7,090 ArriVent BioPharma shares in Q2 2026, an estimated $209K.
  • ArriVent BioPharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2994 holding.
  • Russell Investments Group first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 5 quarters since.
  • 47 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.